




Memorial Sloan Kettering  
Cancer Center

4<sup>th</sup> ANNUAL MSK

# SYMPOSIUM ON LYMPHOMA

State-of-the-Art in  
Biology, Therapy, and Patient Care



**MAY 10-11, 2019**

Memorial Sloan Kettering Cancer Center  
Zuckerman Research Center  
New York, NY

# 4<sup>th</sup> Annual MSK Symposium on Lymphoma

State-of-the-Art in Biology, Therapy, and Patient Care

This symposium will feature updated information on lymphoma biology, diagnosis, immunology, and genetics, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphomas. Faculty will review the current standard of care and present their own perspectives on how they treat various types of lymphomas. Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biologic and genetic biomarkers into clinical practice and clinical trials.

## Educational Objectives

- Provide up-to-date information on recent molecular diagnostic methods
- Provide up-to-date information on recent updates to lymphoma pathology classification
- Provide up-to-date information on recent treatment options for patients with Hodgkin and non-Hodgkin lymphoma

## Target Audience

This symposium is designed for medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.

## MSK Course Director



**Anas Younes, MD**  
Chief, Lymphoma Service

Participants are invited to join the entire course faculty for a networking cocktail reception on Friday evening from 5:20-6:30 PM at Zuckerman Research Center.

## MSK Organizing Committee

Ahmet Dogan, MD, PhD  
Hans Guido Wendel, MD  
Joachim Yahalom, MD, FACR  
Andrew Zelenetz, MD, PhD

## MSK Course Faculty

Maria E. Arcila, MD  
Connie Lee Batlevi, MD, PhD  
Steven M. Horwitz, MD  
Erel Joffe, MD  
Anita Kumar, MD  
Ross L. Levine, MD  
Sham Mailankody, MBBS

## Invited Course Faculty

**Philippe Armand, MD, PhD**  
Dana-Farber Cancer Institute  
Boston, MA

**Elías Campo, MD**  
University of Barcelona  
Spain

**Riccardo Dalla-Favera, MD**  
Columbia University  
New York, NY

**Andrew M. Evens, DO, MSc, FACP**  
Rutgers Cancer Institute of New Jersey  
New Brunswick, NJ

**Massimo Federico, MD**  
University of Modena and Reggio Emilia  
Italy

**Jude Fitzgibbon, PhD**  
Barts Cancer Institute  
England

**Michele Ghielmini, MD**  
Oncology Institute of Southern Switzerland  
Switzerland

**Steven Le Guill, MD**  
University of Nantes  
France

**Michael R. Green**  
The University of Texas  
MD Anderson Cancer Center  
Houston, TX

*Wonderful program  
and speakers; looking  
forward to next year's  
Symposium.*

- 2018 Course Attendee

**Alison J. Moskowitz, MD**  
**Ariela Noy, MD**  
**M. Lia Palomba, MD**  
**Gunjan L. Shah, MD**  
**David J. Straus, MD**  
**Katie Thoren, MD**

**Helen E Heslop, MD, DSc (Hon)**  
Baylor College of Medicine  
Houston, TX

**Peter Johnson MA, MD, FRCP**  
University of Southampton  
United Kingdom

**Ralf Küppers, PhD**  
Institute of Cell Biology (Cancer Research)  
University of Duisburg-Essen  
Germany

**Tak W. Mak, PhD**  
University Health Network  
Canada

**Jürgen Ruland, MD**  
TUM School of Medicine  
Germany


**Reiner Siebert, MD**  
University Hospital Ulm  
Germany

**Louis M. Staudt, MD, PhD**  
National Cancer Institute  
Bethesda, MD

**Laurie Sehn, MD, MPH**  
BC Cancer Agency  
Canada

**David M. Weinstock, MD**  
Dana-Farber Cancer Institute  
Boston, MA

**Pier-Luigi Zinzani, PhD**  
University of Bologna,  
Italy



## Adult BMT Luncheon Panel

---

### Is there a Compelling Role for Hematopoietic Cell Transplantation in Early Relapsed or Refractory Follicular Lymphoma?

Friday, May 10, 12:00-1:00 PM

This luncheon will feature updated information on treatment of hematological malignancies during the dawn of the era of immunotherapies in the form of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Faculty will review the current standard curative therapy (hematopoietic cell transplantation) and how it has evolved. Participants will have the opportunity to ask questions regarding diagnosis and management, and how to determine treatment standards for the best chance of cure.

#### Educational Objectives

- Provide up-to-date information regarding treatment options for patients with early relapsed or refractory Follicular Lymphoma.
- Provide an interactive discussion on potential risks with HCT and non-HCT treatments for hematologic malignancies.

---

**Space is limited for the luncheons and RSVP is required during course registration:  
[mskcc.org/LymphomaCourse](https://mskcc.org/LymphomaCourse)**

## Myeloma Luncheon Panel

---

### Advances in the Treatment and Monitoring of Multiple Myeloma

Saturday, May 11, 12:30-1:30 PM


This luncheon will provide information on use of CAR-T therapy in myeloma and methods to detect low levels of disease by mass spectrometry. Faculty will provide their perspective on the future of these techniques in multiple myeloma. Participants will have the opportunity to discuss how to incorporate these new approaches into clinical practice and clinical trials.

#### Target Audience

This luncheon is intended for medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of hematological malignancies.

#### Educational Objectives

- Understand current data and future directions for CAR T therapy for multiple myeloma.
- Describe the steps to measure immunoglobulins by mass spectrometry.
- List the advantages and disadvantages of MALDI-TOF and QTOF.



## Friday, May 10

7:30 AM BREAKFAST & REGISTRATION

### Department of Medicine Grand Rounds

8:00 AM **Introduction and Welcoming Remarks**  
Anas Younes, MD

8:05 AM **The Molecular Pathogenesis of DLBCL**  
Riccardo Dalla-Favera, MD

9:00 AM **State of the Lymphoma at MSK**  
Anas Younes, MD

### Diffuse Large B Cell Lymphoma

**MODERATOR:** Andrew D. Zelenetz, MD, PhD

9:40 AM **Evolving Frontline Therapy of DLBCL**  
Laurie Sehn, MD, MPH

10:00 AM **CAR T cell Therapy for Lymphoma**  
Helen Heslop, MD, DSc (Hon)

10:20 AM **Primary Mediastinal and Grey Zone Lymphoma**  
Pier-Luigi Zinzani, PhD

10:40 AM **Novel Endpoints in Clinical Trials**  
Andrew D. Zelenetz, MD, PhD

11:00 AM **Identification of DLBL Subtypes Requiring Novel Therapy**  
Peter Johnson MA, MD, FRCP

11:20 AM **Whole Genome Sequencing in DLBCL and FL**  
Ralf Küppers, PhD

11:40 AM **Panel Discussion**

12:00 PM LUNCH BREAK

### Adult BMT Luncheon Panel (Debate)\*

(ROOM 105)

12:00 PM LUNCH & WELCOME

12:10 PM **Hematopoietic Cell Transplantation in Early Relapsed or Refractory Follicular Lymphoma: PRO STANCE**  
Gunjan L. Shah, MD

12:30 PM **Hematopoietic Cell Transplantation in Early Relapsed or Refractory Follicular Lymphoma: CON STANCE**  
Connie Lee Batlevi, MD, PhD

12:50 PM **Voting, Q&A, and Closing Remarks**

### Follicular Lymphoma (FL): Biology

**MODERATOR:** Hans-Guido Wendel, MD

1:00 PM **Novel Molecular Targets in FL**  
Hans-Guido Wendel, MD

1:20 PM **New Insights Into the Biology of Germinal Center Lymphomas**  
Jude Fitzgibbon, PhD

1:40 PM **Targeting the Epigenome of Follicular Lymphoma**  
Michael R. Green

2:00 PM **Current and Novel Treatment Approaches to FL**  
Massimo Federico, MD

2:20 PM **Intercepting FL with Low Tumor Burden**  
Michele Ghilmini, MD

2:40 PM **Role of Radiation Therapy**  
Joachim Yahalom, MD, FACR

3:00 PM **What Can We Learn from Rare FL Variants**  
David M. Weinstock, MD

3:20 PM **Panel Discussion**

3:40 PM BREAK

### Mantle Cell Lymphoma

**MODERATOR:** Ariela Noy, MD

4:00 PM **Biology of MCL**  
Elías Campo, MD

4:20 PM **Management of Newly Diagnose MCL: Are We Ready for Chemo Free Approach**  
Steven Le Gouill, MD

4:40 PM **Outcome of Relapsed MCL in the Modern Era**  
Anita Kumar, MD

5:00 PM **Panel Discussion**

5:20 PM ADJOURN

### Networking Cocktail Reception

Participants are invited to join course director, Dr. Anas Younes, and the entire course faculty for a cocktail reception on Friday evening from 5:20-6:30 PM at Zuckerman Research Center.

Please RSVP during course registration

## Saturday, May 11

7:30 AM BREAKFAST

### Clinical Application of Genome Sequencing

**MODERATOR:** Ahmet Dogan, MD, PhD

8:00 AM **Introduction to Clinical Diagnostic Genome Sequencing**

Maria E. Arcila, MD

8:30 AM **Clonal Hematopoiesis**

Ross L. Levine, MD

9:00 AM **Molecular Classification of DLBCL**

Louis M. Staudt, MD, PhD

9:30 AM **Can We Apply DLBCL Genetic Classification to Targeted Sequencing Panels**

Erel Joffe, MD

9:45 AM **Panel Discussion**

10:15 AM BREAK

### Hodgkin Lymphoma

**MODERATOR:** Anas Younes, MD

10:30 AM **Frontline Therapy**

David J. Straus, MD

10:50 AM **Checkpoint Inhibitors**

Philippe Armand, MD, PhD

11:10 AM **Therapy of Relapsed HL**

Alison J. Moskowitz, MD

11:30 AM **HL in the Elderly**

Andrew M. Evens, DO, MSc, FACP

11:50 AM **Panel Discussion**

12:30 PM LUNCH BREAK

### Myeloma Luncheon Panel\*

(ROOM 105)

12:30 PM LUNCH & WELCOME

12:40 PM **CAR T cell Therapy for Multiple Myeloma**

Sham Mailankody, MBBS

1:00 PM **Mass Spectrometry for the Detection of Monoclonal Immunoglobulins**

Katie Thoren, MD

1:20 PM **Q&A and Closing Remarks**

### T Cell Lymphoma

**MODERATOR:** Steven M. Horwitz, MD

1:30 PM **Therapy of Newly Diagnosed Patients**

Steven M. Horwitz, MD

1:50 PM **Can a Lymphoma Cell Think?**

Tak W. Mak, PhD

2:10 PM **Immune Receptor Signals in T Cell Lymphoma**

Jürgen Ruland, MD

2:30 PM **Panel Discussion**

3:00 PM BREAK

### Marginal Zone, Waldenstrom, and Rare Lymphomas

**MODERATOR:** M. Lia Palomba, MD

3:20 PM **Molecular Biology of Rare Lymphoma Subtypes**

Reiner Siebert, MD

3:40 PM **Marginal Zone Lymphoma**

Ariela Noy, MD

4:00 PM **Waldenstrom Macroglobulinemia**

M. Lia Palomba, MD

4:20 PM **Panel Discussion**

4:45 PM **Closing Remarks**

Anas Younes, MD

5:00 PM ADJOURN

### Live Simulcast Available

We are pleased to offer a live simulcast for the 4th Annual MSK Symposium on Lymphoma, available to attendees unable to attend this course in person. CME credit will still be offered for the live simulcast and active participation is required throughout the symposium. We do hope you will attend in person but understand that can sometimes be a challenge so we are happy to offer the live simulcast as an option.

Please visit [mskcc.org/LymphomaCourse](http://mskcc.org/LymphomaCourse) for details or to register.

## Registration

REGISTRATION FEES	EARLY*	GENERAL
Physicians (MDs, PhDs, and DOs)	\$350	\$400
Nurses, PAs, and Other Healthcare Professionals	\$150	\$200
Residents and Fellows	\$100	\$150
Industry Professionals**	\$650	\$700

\*Early registration rate expires January 31, 2019.

\*\*Industry and Professionals may attend CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

### Register online: [mskcc.org/LymphomaCourse](https://mskcc.org/LymphomaCourse)

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact [cme@mskcc.org](mailto:cme@mskcc.org) at least one week prior to the course if you have any special dietary needs.

- **30% Discounted Rate for MSK Alumni and MSK Alliance Members:** MSK offers a 30% discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact [cme@mskcc.org](mailto:cme@mskcc.org) for promotion code or more information.
- **MSK Staff Registration:** Registration is complimentary for MSK staff. However, you must register online: [mskcc.org/LymphomaCourse](https://mskcc.org/LymphomaCourse).

#### Accreditation Statement

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



#### AMA Credit Designation Statement

MSK designates this live activity for a maximum of **17.50 AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity.

#### Faculty Disclosure

It is the policy of MSK to make every effort to ensure balance, independence, objectivity, and scientific rigor in all continuing medical education activities it offers as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer of any commercial product and/or provider of commercial services which are discussed by them in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.



#### Symposium Location

Memorial Sloan Kettering Cancer Center  
Zuckerman Research Center  
417 East 68th Street  
New York, NY 10065

#### Accommodations

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, please visit: [mskcc.org/cme](https://mskcc.org/cme).

#### Contact

Memorial Sloan Kettering Cancer Center  
Office of Continuing Medical Education  
**646-227-2025**  
[cme@mskcc.org](mailto:cme@mskcc.org)



Memorial Sloan Kettering  
Cancer Center